Ajay Kumar Goel

US Patent:

20120088687, Apr 12, 2012

Filed:

Oct 7, 2011

Appl. No.:

13/269059

Inventors:

Ajay Goel - Dallas TX, US
C. Richard Boland - Dallas TX, US
Francesc Balaguer - Barcelona, ES
Meritxell Gironella i Cos - Barcelona, ES
Antoni Castells i Garangou - Barcelona, ES
Leticia Moreira Ruiz - Barcelona, ES
Juan Jose Lozano Salvatella - Barcelona, ES

Assignee:

Baylor Research Institute - Dallas TX
Centro de Investigacion en Red de Enfermedades Hepaticas y Digestivas (CIBEREHD) - Barcelona
Hospital Clinic de Barcelona - Barcelona

International Classification:

C40B 30/04
C40B 40/06

US Classification:

506 9, 506 16

Abstract:

A technique for the analysis of global miRNA signatures including a larger panel of miRNAs in various groups of well-characterized colorectal cancers (CRCs) is described in the instant invention. The results presented herein provide a large list of miRNAs that are dysregulated in CRC compared to the normal colonic tissue, and, more importantly, the present invention shows for the first time that Lynch syndrome and sporadic MSI tumors exhibit a different miRNA signature that distinguishes them.

US Patent:

20120207856, Aug 16, 2012

Filed:

Feb 10, 2012

Appl. No.:

13/370752

Inventors:

Ajay Goel - Dallas TX, US
C. Richard Boland - Dallas TX, US
Minoru Koi - Dallas TX, US
Masanobu Takahashi - Richardson TX, US

Assignee:

Baylor Research Institute - Dallas TX

International Classification:

A61K 33/24
A61K 31/255
A61K 31/196
A61K 31/675
A61K 31/655
C07K 14/47
A61K 31/4745
C12Q 1/68
G01N 33/53
G01N 33/566
G01N 33/577
A61P 35/00
A61K 31/175
A61K 31/704

US Classification:

424649, 514589, 514517, 514567, 514110, 514151, 514 34, 514283, 435 612, 436501, 435 723, 530350

Abstract:

Methods for treating a patient at risk for or diagnosed with colorectal cancer are disclosed herein. The method of the present invention determines the overall expression of MSH3 in cells suspected of being colorectal cancer cells from the patient and predicting the efficacy of therapy with a genotoxic anti-neoplastic agent for treating the patient, wherein a decrease in the overall expression of MSH3 in the patient cells when compared to the expression of MSH3 in normal colorectal cells indicates a predisposition to responsiveness to genotoxic anti-neoplastic agent therapy, wherein the therapy comprises administering an effective amount of the genotoxic anti-neoplastic agent therapy to patients.

US Patent:

20120237929, Sep 20, 2012

Filed:

Feb 29, 2012

Appl. No.:

13/408947

Inventors:

Ajay Goel - Dallas TX, US
C. Richard Boland - Dallas TX, US
Keun Hur - Dallas TX, US

Assignee:

BAYLOR RESEARCH INSTITUTE - Dallas TX

International Classification:

C12Q 1/68
C07H 21/04

US Classification:

435 611, 536 235

Abstract:

A method for determining a colorectal cancer metastasis in a human subject suffering from a primary colorectal cancer (CRC) is described herein. The method of the present invention comprises the steps of: i) identifying the human subject suffering from the primary CRC, ii) obtaining one or more biological samples from the human subject, iii) detecting a methylation level of Alu, LINE-1, or both in the one or more biological samples, and iv) increasing the level of the colorectal metastatic stage in the human subject when the methylation level of Alu, LINE-1 is lower compared to a corresponding control methylation level of Alu, LINE-1.

US Patent:

20120238463, Sep 20, 2012

Filed:

Mar 14, 2012

Appl. No.:

13/419744

Inventors:

Ajay Goel - Dallas TX, US
C. Richard Boland - Dallas TX, US
Francesc Balaguer - Barcelona, ES

Assignee:

Baylor Research Institute - Dallas TX

International Classification:

C12Q 1/68
C40B 30/04
C40B 30/00

US Classification:

506 9, 435 611, 506 7

Abstract:

A method for detecting an early-onset of colorectal cancer in a human subject is disclosed herein. The method comprises the steps of: (i) identifying the human subject suspected of suffering from a colorectal cancer, (ii) obtaining one or more biological samples from the human subject; (iii) determining a LINE-1 methylation level for the one or more biological samples; and (iv) comparing the LINE-1 methylation level to a LINE-1 methylation control level, wherein a higher degree of the LINE-1 methylation level is indicative of an early-onset colorectal cancer.

US Patent:

20120264131, Oct 18, 2012

Filed:

Feb 29, 2012

Appl. No.:

13/408836

Inventors:

Ajay Goel - Dallas TX, US
C. Richard Boland - Dallas TX, US
Keun Hur - Dallas TX, US

Assignee:

BAYLOR RESEARCH INSTITUTE - Dallas TX

International Classification:

C12Q 1/68
C07H 21/02

US Classification:

435 612, 435 614, 536 231

Abstract:

The present invention includes methods, kits and biomarkers for detecting and determining the development of colorectal cancer (CRC) metastasis based on changes in the expression pattern of one or more microRNAs (miR) or miR clusters that include the miR-200/141 family.

US Patent:

20120295267, Nov 22, 2012

Filed:

May 7, 2012

Appl. No.:

13/465668

Inventors:

Ajay Goel - Dallas TX, US
C. Richard Boland - Dallas TX, US
Takeshi Nagasaka - Okayama, JP

Assignee:

Baylor Research Institute - Dallas TX

International Classification:

C12Q 1/68
C12M 1/40

US Classification:

435 612, 4352872

Abstract:

Use of a CAT25 mononucleotide marker in a novel tetraplex PCR for the detection of MSH6-defective colorectal cancers (CRCs) is described herein. The tetraplex PCR of the present invention offers a facile, robust, less expensive (compared to the original pentaplex assay), highly sensitive, and specific assay for the identification of microsatellite instability (MSI) in CRCs.

US Patent:

20130288247, Oct 31, 2013

Filed:

Oct 4, 2011

Appl. No.:

13/876568

Inventors:

Yuriko Mori - Baltimore MD, US
Stephen Meltzer - Lutherville MD, US
Ajay Goel - Dallas TX, US
Clement Boland - Dallas TX, US

Assignee:

The Johns Hopkins University - Baltimore MD

International Classification:

C12Q 1/68

US Classification:

435 611

Abstract:

The present invention relates to the field of cancer. More specifically, the present invention relates to the use of biomarkers to detect colorectal cancer. In one aspect, the present invention provides methods for qualifying colorectal cancer status including, but not limited to, diagnosis, prognosis, and risk stratification, in patients. In one embodiment, a method for diagnosing colorectal cancer (CRC) in a patient comprises the steps of (a) collecting a sample from the patient; (b) measuring the methylation levels of one or more biomarkers in the sample collected from the patient; and (c) comparing the methylation levels of the one or more biomarkers with predefined methylation levels of the same biomarkers that correlate to a patient having CRC and predefined methylation levels of the same biomarkers that correlate to a patient not having CRC, wherein a correlation to one of the predefined methylation levels provides the diagnosis.

US Patent:

20110086353, Apr 14, 2011

Filed:

Oct 8, 2010

Appl. No.:

12/901467

Inventors:

Ajay Goel - Dallas TX, US
C. Richard Boland - Dallas TX, US
Alexander Link - Dallas TX, US
Francesc Balaguer - Dallas TX, US

Assignee:

BAYLOR RESEARCH INSTITUTE - Dallas TX

International Classification:

C12Q 1/68
C12P 19/34

US Classification:

435 6, 435 912, 435 9121

Abstract:

A simple, rapid, inexpensive, and promising commercial biomarker assay method for multiple diseases is described herein. The present invention detects miRNA-based biomarkers in human stool specimens. The method of the present invention amplifies miRNA directly from stool specimens without any prior miRNA extraction. Differential expression of specific microRNAs in stool of colorectal cancer CRC and adenoma patients suggest fecal microRNAs as a novel potential biomarker for colorectal neoplasia detection. The method of the present invention has diagnostic, prognostic, and therapeutic relevance for gastroenterological cancers/colorectal cancer and as well as further acquired or hereditary GI diseases.